ReviewNature protocols2026
Synthesis and guest inclusion for molecular catcher-based structure determination.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Natural products and drugs containing long alkyl chains are difficult to grow in the form of single crystals. This makes it challenging, if not impossible, to determine their molecular structures through conventional single-crystal X-ray diffraction. We recently reported a 'molecular catcher' technique using a pillar[5]arene-incorporated metal-organic framework (MOF), namely a 'molecular catcher', that enables rapid and accurate determination of crystal structures for long-alkyl-chain compounds without a need to grow single crystals. In this approach, presynthesized pillar[5]arene-containing MOF crystals are soaked in a solution of the target compound. The compound is captured into the MOF crystals, which are then analyzed by X-ray diffraction, allowing the crystal structure of the guest to be determined. Here we describe detailed protocols for the synthesis of this pillar[5]arene-containing MOF and its further use in structure determinations. In brief, the MOF crystals required for this Protocol are prepared from an in-house synthesized pillar[5]arene derivative, a commercially available tetraphenyl ethylene derivative and zinc nitrate hexahydrate in N,N-dimethylformamide. The resulting crystals are washed with fresh N,N-dimethylformamide to remove unreacted starting materials and can be used directly for guest inclusion without further solvent exchange. The most critical step is selecting MOF crystals with suitable size and quality. We recommend using optical microscopy for preliminary screening to evaluate crystal size and quality as the selection criteria. By soaking the MOF crystals in a solution of the target compound, target-included MOF crystals suitable for X-ray diffraction analysis can be obtained. The entire process-from starting materials to determining the crystal structure-can be completed within 10 d.
Identifiers
42204339What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.